ObsEva Presents PROLONG Phase 2a Proof-of-Concept Data on Ebopiprant (OBE022) for the Treatment of Spontaneous Preterm Labor at the RCOG Virtual World Congress 2021
10. Juni 2021 01:00 ET
|
ObsEva SA
-PROLONG data demonstrating ebopiprant was well tolerated and showed early evidence of efficacy selected for presentation- - Phase 2b/3 adaptive dose-ranging study planned to initiate in Q4:21- ...
ObsEva Announces Oral Presentation at the RCOG Virtual World Congress 2021
02. Juni 2021 01:00 ET
|
ObsEva SA
- Data from PROLONG Phase 2a proof-of-concept study of ebopiprant (OBE022) for spontaneous preterm labor to be discussed in an oral presentation - GENEVA, Switzerland and BOSTON, MA – June 2, 2021 –...
ObsEva SA Reports Positive Topline Results of the PROLONG Proof-of-Concept Trial of Ebopiprant (OBE022) for Treatment of Preterm Labor
16. November 2020 01:00 ET
|
ObsEva SA
Over 50% reduction of pre-term delivery within 48hrs of treatment in singleton pregnancyMaternal, fetal and neonatal safety comparable to placeboData supports advancement of ebopiprant to Phase 2b...
ObsEva SA Reports Positive Feedback from Independent Data Monitoring Committee for PROLONG Part B with OBE022
26. Juli 2019 01:00 ET
|
ObsEva SA
Geneva, Switzerland and Boston, MA – July 26, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel...
ObsEva SA to Present OBE022 Clinical Data for Treatment of Pre-term labor (PTL) at the SRI 66th Annual Scientific Meeting, March 12 -16, 2019
13. März 2019 02:00 ET
|
ObsEva SA
Geneva, Switzerland and Boston – March 13, 2019 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel...
Update: ObsEva SA Reports Initial Good Safety of OBE022 in Pregnant Women with Preterm Labour and Announces Start of Part B of the PROLONG Trial
23. Januar 2019 03:28 ET
|
ObsEva SA
Geneva, Switzerland and Boston, MA – January 23, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel...
ObsEva SA Reports Initial Good Safety of OBE022 in Pregnant Women with Preterm Labour and Announces Start of Part B of the PROLONG Trial
23. Januar 2019 01:00 ET
|
ObsEva SA
Geneva, Switzerland and Boston, MA – January 23, 2018 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel...